Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 12/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13031134 | 0.93 | PTGS2 (0.35) | GRIN2BPTGS2PTGS1ALK | |
| SCHEMBL13031155 | 0.90 | PTGS2 (0.33) | GRIN2BPTGS2PTGS1TP53POLB | |
| SCHEMBL13031262 | 0.86 | NPY5R (0.35) | GRIN2BPTGS2PTGS1TP53NPY5R | |
| SCHEMBL13031479 | 0.86 | NAMPT (0.36) | GRIN2BPTGS2PTGS1 | |
| SCHEMBL13031310 | 0.85 | GRIN2B (0.34) | GRIN2BPTGS2PTGS1ALK | |
| SCHEMBL3584110 | 0.85 | IRAK4 (0.34) | GRIN2BTP53POLBMAPT | |
| SCHEMBL13031372 | 0.84 | PTGS2 (0.35) | GRIN2BPTGS2PTGS1 | |
| SCHEMBL13031191 | 0.84 | GRIN2B (0.33) | GRIN2BPTGS2PTGS1 | |
| SCHEMBL13031140 | 0.84 | PTGS2 (0.36) | GRIN2BPTGS2PTGS1NPY5RALK | |
| SCHEMBL13031322 | 0.84 | CXCR3 (0.40) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | GRIN2B 584/4885PTGS2 311/4885PTGS1 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.